Review
Version 1
Preserved in Portico This version is not peer-reviewed
Aptamer Applications in Neuroscience
Version 1
: Received: 2 November 2021 / Approved: 4 November 2021 / Online: 4 November 2021 (09:49:50 CET)
A peer-reviewed article of this Preprint also exists.
Ozturk, M.; Nilsen-Hamilton, M.; Ilgu, M. Aptamer Applications in Neuroscience. Pharmaceuticals 2021, 14, 1260. Ozturk, M.; Nilsen-Hamilton, M.; Ilgu, M. Aptamer Applications in Neuroscience. Pharmaceuticals 2021, 14, 1260.
DOI: 10.3390/ph14121260
Abstract
Being the predominant cause of disability, neurological diseases have received much attention from the global health community. Over a billion people suffer from one of the following neurological disorders: dementia, epilepsy, stroke, migraine, meningitis, Alzheimer's disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, prion dis-ease, or brain tumors. Diagnosis and treatment options are limited for many of these diseases. Aptamers, being small and non-immunogenic nucleic acid molecules that are easy to chemically modify, offer potential diagnostic and theranostic applications to meet these needs. This review covers pioneer studies to apply aptamers, which show promise for future diagnostics and treatments of neurological disorders that pose increasingly dire worldwide health challenges.
Keywords
aptamer; neuroscience; neurological diseases; neurological disorders; neurotoxins; cancer
Subject
LIFE SCIENCES, Biochemistry
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
